PMID- 33089969
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 2056-4538 (Electronic)
IS  - 2056-4538 (Linking)
VI  - 7
IP  - 1
DP  - 2021 Jan
TI  - An analysis of HER2 amplification in cervical adenocarcinoma: correlation with 
      clinical outcomes and the International Endocervical Adenocarcinoma Criteria and 
      Classification.
PG  - 86-95
LID - 10.1002/cjp2.184 [doi]
AB  - Few studies have explored HER2 status in cervical adenocarcinoma, particularly in 
      the gastric-type adenocarcinoma (GAC), a nonhuman-papillomavirus-related subtype 
      with poor clinical outcomes. In this study, we investigated HER2 expression and 
      amplification by immunohistochemistry (IHC) and fluorescence in situ 
      hybridization (FISH) in 209 well annotated cervical adenocarcinomas diagnosed 
      using the International Endocervical Adenocarcinoma Criteria and Classification. 
      IHC identified HER2 protein expression in 57.4% (123/209) of adenocarcinomas, of 
      which 62 were IHC 1+ (negative), 38 2+ (equivocal) and 23 3+ (positive). HER2 
      amplification was found in 13 cases (6.2%) including 10 with IHC 3+ and 3 with 
      IHC 2+. Among all the major histotypes of cervical adenocarcinoma, HER2 
      amplification was most common in GAC cases with a frequency of 14.7% (5/34). 
      Moreover, HER2 amplification was more frequently associated with 2018 
      International Federation of Gynecology & Obstetrics (FIGO) stage III/IV, 
      perineural involvement and ovarian spread (p < 0.05) while IHC 3+ was more common 
      in patients with lymphovascular invasion and ovarian involvement (p < 0.05). 
      Survival analysis indicated that FIGO stage III/IV, GAC, and p53 overexpression 
      were associated with poor disease-specific survival and tumor recurrence 
      (p < 0.05). In conclusion, HER2 amplification was present in a subset of 
      adenocarcinomas, and more common in GAC, pointing to a potential benefit from 
      trastuzumab treatment. HER2 overexpression does not identify gene amplification 
      status in cervical adenocarcinoma; therefore, FISH is suggested for both IHC 
      positive and equivocal cases. Further investigation on more cases with longer 
      follow-up times is required to consolidate these findings.
CI  - (c) 2020 The Authors. The Journal of Pathology: Clinical Research published by The 
      Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.
FAU - Shi, Haiyan
AU  - Shi H
AD  - Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang 
      University, Hangzhou, PR China.
FAU - Shao, Ying
AU  - Shao Y
AD  - Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang 
      University, Hangzhou, PR China.
FAU - Lu, Weiguo
AU  - Lu W
AD  - Center for Uterine Cancer Diagnosis and Therapy Research of Zhejiang Province, 
      Women's Hospital, Zhejiang University, Hangzhou, PR China.
AD  - Department of Gynecological Oncology, Women's Hospital, School of Medicine, 
      Zhejiang University, Hangzhou, PR China.
FAU - Lu, Bingjian
AU  - Lu B
AD  - Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang 
      University, Hangzhou, PR China.
AD  - Center for Uterine Cancer Diagnosis and Therapy Research of Zhejiang Province, 
      Women's Hospital, Zhejiang University, Hangzhou, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201022
PL  - England
TA  - J Pathol Clin Res
JT  - The journal of pathology. Clinical research
JID - 101658534
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adenocarcinoma/*genetics/pathology/therapy
MH  - Adult
MH  - Antineoplastic Agents, Immunological/therapeutic use
MH  - Biomarkers, Tumor/antagonists & inhibitors/*genetics
MH  - Clinical Decision-Making
MH  - Female
MH  - *Gene Amplification
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/antagonists & inhibitors/*genetics
MH  - Trastuzumab/therapeutic use
MH  - Treatment Outcome
MH  - Uterine Cervical Neoplasms/*genetics/pathology/therapy
PMC - PMC7737776
OTO - NOTNLM
OT  - HER2
OT  - HPV
OT  - cervical adenocarcinoma
OT  - gastric-type
OT  - gene amplification
OT  - prognosis
EDAT- 2020/10/23 06:00
MHDA- 2021/10/14 06:00
PMCR- 2020/10/22
CRDT- 2020/10/22 08:49
PHST- 2020/08/23 00:00 [received]
PHST- 2020/09/20 00:00 [revised]
PHST- 2020/09/22 00:00 [accepted]
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/10/22 08:49 [entrez]
PHST- 2020/10/22 00:00 [pmc-release]
AID - CJP2184 [pii]
AID - 10.1002/cjp2.184 [doi]
PST - ppublish
SO  - J Pathol Clin Res. 2021 Jan;7(1):86-95. doi: 10.1002/cjp2.184. Epub 2020 Oct 22.